Clinical Trials Logo

Clinical Trial Summary

In a prospective, randomized clinical trial the iPOST2 trial will determine whether ischemic postconditioning reduces reperfusion injury and this will translate into improved clinical outcome of heart failure and death for STEMI patients who present with TIMI0-1 undergoing primary PCI


Clinical Trial Description

Myocardial reperfusion with the use primary percutaneous coronary intervention (PCI) is effective, but restoration of blood flow may itself jeopardize the myocardium, a phenomenon known as reperfusion injury. In ischemic postconditioning (iPOST), repetitive interruptions of blood flow to the injured region applied after initial reperfusion, has been shown favorable with different modalities such as biomarkers, echocardiography and cardiac magnetic resonance. However, the largest trial to date (DANAMI3-iPOST) failed to show clinical favor of iPOST when compared to conventional PCI. Importantly, however, in DANAMI3-iPOST thrombectomy was allowed and this might have impaired postconditioning, since thrombectomy itself creates reperfusion and thus reperfusion damage. Analysis of the fraction of DANAMI3-iPOST patients not undergoing thrombectomy showed a remarkable 45% reduction in death and heart failure in favor of postconditioning. iPOST2 will investigate in a randomized, prospective and adequately powered trial the effect of iPOST without thrombectomy compared to conventional PCI on the development of heart failure and death in STEMI patients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03787745
Study type Interventional
Source Rigshospitalet, Denmark
Contact Thomas Engstrøm, DMSci
Phone +4535458444
Email thomas.engstroem@regionh.dk
Status Recruiting
Phase N/A
Start date February 4, 2019
Completion date January 31, 2033

See also
  Status Clinical Trial Phase
Recruiting NCT02869906 - Instantaneous Wave-Free Ratio and Fractional Flow Reserve for the Assessment of Non Culprit Lesions in Patients With ST-segment Elevation Myocardial Infarction N/A
Not yet recruiting NCT03895983 - ST Segment Resolution After Primary Percutaneous Coronary Intervention.
Not yet recruiting NCT03252665 - Efficacy of Intracoronary Infusion of Different Medicine in STEMI Patients Undergoing Primary PCI Phase 4
Completed NCT02026219 - Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in ST-Segment Elevation Myocardial Infarction Phase 4
Completed NCT03247738 - Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI Phase 4
Recruiting NCT05461781 - Distal Transradial Access for Primary PCI in STEMI Patients to Prevent RAO N/A
Recruiting NCT03561389 - iFR-guided Revascularization in STEMI
Completed NCT01538303 - Microvascular Dysfunction in Acute Myocardial Infarction (AMI) and Its Relation to Outcome
Recruiting NCT02979236 - Italian Multi-center Registry of Self-apposing Coronary Stent in Patients With STEMI N/A
Completed NCT05705089 - Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI Phase 3
Completed NCT01897350 - Myocardial Oedema in ST Segment Elevation Myocardial Infarction Myocardial N/A
Not yet recruiting NCT03753269 - Early Intracoronary Administration of Fasudil in the Primary PCI of ST-segment-Elevation Myocardial Infarction Phase 4
Completed NCT03234348 - MAGnesium-based Bioresorbable Scaffold in ST Segment Elevation Myocardial Infarction Phase 3
Recruiting NCT03406832 - Prevention of Coronary Slow Flow or No-Reflow During EPCI in Patients With Acute STEMI N/A
Recruiting NCT03406819 - Prevention of Coronary Slow Flow or No-Reflow During PPCI in Patients With Acute STEMI N/A
Recruiting NCT03508232 - Doxycycline to Protect Heart Muscle After Heart Attacks Phase 2
Recruiting NCT04220736 - Early Prediction of QFR in STEMI-Pharmaco-invasice
Completed NCT03780335 - Early Prediction of QFR in STEMI-I
Recruiting NCT03621111 - A Trial on the Role of Community Pharmacist in Improving Adherence and Clinical Outcomes in Post-Infarction N/A
Recruiting NCT03764241 - Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant Phase 3